Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111904 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Theradex.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT00111904: Completed Phase 2 study of Pancreatic Cancer, sponsored by Theradex.
NCT00111904 is a Phase 2 study of Pancreatic Cancer that has completed, run by Theradex. The registered enrollment target is 43 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111904, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Theradex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel works in treating patients with unresectable locally advanced or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG paclitaxel-loaded polymeric micelle
Study Locations (5)
Florida
- Florida Cancer Specialists - Bonita Springs - Bonita Springs
Illinois
- Midwest Cancer Research Group, Incorporated - Skokie
Louisiana
- Louisiana Oncology Associates - Lafayette - Lafayette
New York
- St. Vincent's Comprehensive Cancer Center - Manhattan - New York
Texas
- Southwest Regional Cancer Center - Central - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-05 |
| Phase | Phase 2 |
What the finished NCT00111904 record still lists
NCT00111904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which paclitaxel-loaded polymeric micelle is the first listed.
NCT00111904 lists 5 locations in 5 states (Florida, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT00111904 about?
NCT00111904 is a clinical study titled "Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel works in treating patients with unresectable locally advan...
What is the current status of trial NCT00111904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2005-05.
What conditions does trial NCT00111904 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00111904?
The interventions under investigation include: paclitaxel-loaded polymeric micelle (DRUG).
Who is sponsoring clinical trial NCT00111904?
This trial is sponsored by Theradex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111904 being conducted?
This trial has 5 study locations across Florida, Illinois, Louisiana, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00111904's enrollment target sits among peer trials
43 166th of 278 higher than 113 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia